"Why did Genentech sign up to a study into the efficacy of stapled peptides in disease pathways in cancer? Were Genentech surprised by the findings that the two stapled peptides 'didn't perform as claimed' or did Genentech suspect beforehand that the staple didn't 'enhance cell permeability or binding affinity'?"
I'd say Genentech are still pretty much on their high horse for their position in the science side of things. They were always the kings of the science that got taken over by Roche the corporate behemoth not saying that Roche are under the bar but it's kind of like the geeks wearing their sneakers & track pants to work against the suits in black ties & white shirts there's always some kind of competition in there & someone always likes to be right :-)
Although still strange considering who now holds power.
PYC Price at posting:
2.2¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)